Applied DNA Sciences

Exhibitor

LineaRx, a subsidiary of Applied DNA Sciences, Inc. (NASDAQ: APDN), delivers enzymatically-produced LineaDNA™ - a faster, purer, and scalable alternative to plasmid-based DNA manufacturing. Powered by proprietary large-scale PCR-based technologies, LineaDNA enables the rapid, cell-free production of high-fidelity DNA sequences.

Linea DNA supports a broad spectrum of advanced therapeutics, including mRNA production, DNA vaccines, cell and gene therapies, and veterinary applications. Founded in 2018 to commercialize over 20 years of expertise in enzymatic DNA production, LineaRx is driving the future of DNA-based medicines.

website